Abstract: A drug-filled synthetic resin ampule has an ampule body capable of standing by itself and a drug accommodated inside the ampule body. The ampule body has a tip part positioned at an upper part thereof when the ampule body stands by itself, a hollow part having a drug accommodation portion, and a breakable part provided between a lower portion of the tip part and an upper portion of the hollow part. The tip part has pressing portions, for guiding a pressing force applied thereto respectively in a predetermined direction when an operation of breaking the breakable part is performed. The hollow part has a bottom surface part for allowing the ampule body to stand by itself. The bottom surface part has extension portions extended in predetermined directions (X-direction, Y-direction) in which the pressing force applied to the pressing portions respectively is guided when the operation of pressing the pressing portion is performed to break the breakable part.

Abstract: An article or vessel is described including a vessel surface and a coating set comprising at least one tie coating, at least one barrier coating, and at least one pH protective coating. For example, the coating set can comprise a tie coating, a barrier coating, a pH protective coating and a second barrier coating; and in the presence of a fluid composition, the fluid contacting surface is the barrier coating or layer. The respective coatings can be applied by PECVD of a polysiloxane precursor. Such vessels can have a coated interior portion containing a fluid with a pH of 4 to 8. The barrier coating prevents oxygen from penetrating into the thermoplastic vessel, and the tie coating and pH protective coating together protect the barrier layer from the contents of the vessel. The second barrier coating is comparable to glass surface if needed.

Abstract: The device allows the connection between a vessel closed off by a perforable stopper and a container. It comprises a base, which is configured to be mounted on the vessel and which comprises a hollow member for perforating the stopper, this hollow member delimiting at least one opening, and a needle holder, which is waiting to be connected with the container, and which includes a needle, one of the ends of which emerges in the inner volume of the hollow member. The device further comprises a collar attached to a needle holder, and a sheath, which is connected around the collar and which defines a central axis along which it is movable against a resilient force exerted by a spring.

Abstract: A device is provided for monitoring the delivery and taking of medication pills by detecting both the passage of a pill and the covering of a pill outlet region, which is indicative of an active operation of the user to remove the pill from the pill outlet region. In this way, pill delivery can be monitored as well as an indication of actual pill taking.

Abstract: A tooth whitening method uses an application device having a reservoir containing an oxidizing composition comprising a fluid carrier and an oxidizing agent, an applicator member in fluid communication with the reservoir, and a dispensing mechanism for moving contents of the reservoir into the applicator member. The oxidizing composition is dispensed into the applicator member by actuating the dispensing mechanism and is applied to one or more teeth in an oral cavity. Then, a sealant composition is applied to the teeth having the oxidizing agent thereon to form a coating that resists moisture contamination of the previously applied oxidizing agent. One embodiment uses an oxidizing composition with a viscosity less than 150 cps that is absorbed in a porous material in the device reservoir, from which it is introduced by capillary action into a porous applicator member.

Abstract: The invention relates to novel multicolour, multitexture and multimaterial cosmetic products as well as to a method for hot casting cosmetic compositions containing fats, in particular an oil. Said method advantageously renders a mold superfluous and allows the creation of products that include a plurality of compositions such as to produce highly original appearances. Said method also allows the production of products with a very irregular raised designs.

Abstract: This invention relates to an improved crystallization process of hydrogenated castor oil structurant which results in (i) a dispersion having a high concentration of the structurant, and (ii) a crystal habit/form that results in a higher yield stress in the final product, imparting high stability, for a given amount structurant. In addition, the resulting personal care product is consumer desired, as less structurant residue is observed on hair after the use of the personal care product.

Abstract: Disclosed are: a co-emulsified composition containing different emulsification particle sizes; and a method for preparing the same. The co-emulsified composition contains an amphipathic anisotropic power and a surfactant, thereby allowing emulsification particles with different sizes to coexist in one dosage form, and thus a co-emulsified composition can be provided that simultaneously implements two or more feelings of use or physical characteristics.

Abstract: This invention provides for a thin emulsion base for cosmetic products with low to medium viscosity. The bases are excipients that provide stability to cosmetic products. The thin emulsion bases of this invention are from non-synthetic and non-petroleum based products and comprise over 80% juice derived solvents with the balance being a combination of alkane texture enhancers and lipid emulsifiers.

Abstract: The present invention relates to improved complexes of amorphous calcium phosphate and/or amorphous calcium fluoride phosphate stabilised by phosphopeptides/phosphoproteins by addition of stannous ions. These complexes have anticariogenic properties useful to protect tooth structures as they remineralize (repair) early stages of dental caries and have other dental/medical applications (including anti-calculus, anti-erosion/corrosion and anti-dentinal hypersensitivity). Methods of making the complexes of the invention and of treatment or prevention of various dental conditions including dental caries, dental calculus, dental erosion/corrosion and dental hypersensitivity are also provided.

Abstract: Disclosed is a hair conditioning composition comprising: (a) a cationic surfactant; (b) a high melting point fatty compound having a melting point of 25° C. or higher; (c) a monoalkyl glyceryl ether; and (d) an aqueous carrier. The compositions of the present invention provide styling and/or volume benefits together with conditioning benefits.

Abstract: The invention relates to compositions for removing nail polish comprising at least at least about 10% by weight of at least one polyhydric alcohol compound, at least one low carbon alcohol, at least one high boiling point ester compound, at least one thickening agent, and at least one abrasive compound, as well as to methods of removing nail polish from nails using such compositions.

Abstract: A liquid cleansing composition comprising water in an amount sufficient to form a liquid composition, a fatty acid soap, a structuring agent, and talc. The cleansing composition has a creamy texture and provides good skinfeel properties.

Abstract: A method for shaping keratin fibres, wherein the method comprises: applying a reducing composition to keratin fibres; rinsing the keratin fibres; applying a fixing composition to keratin fibres, wherein the fixing composition comprises a crosslinking agent, wherein the crosslinking agent has at least two functional groups selected from the group consisting of: —NH2, —NH—, —SH, —OH, —C(?O)H, —C?O, and —COOH, and wherein the crosslinking agent has a molecular weight of 500 g/mol or less; drying the keratin fibres; treating the keratin fibres with a shaping appliance; optionally rinsing the keratin fibres. Also a related use and kit.

Abstract: Disclosed herein is hair cosmetic composition comprising a thiol-based compound selected from thiolactic acid and its derivatives or salts, and wherein the composition has a pH of less than 7. Also disclosed is a process for shaping or 5 altering the shape of hair or caring of the hair.

Abstract: The invention relates to a cosmetic composition comprising: one or more linear ?-olefin sulfonates, one or more anionic surfactants present in the composition in an amount ranging from 1% to 20% by weight; and one or more additional surfactants chosen from amphoteric surfactants and nonionic surfactants, the weight ratio of the amount of linear ?-olefin sulfonates to the amount of anionic surfactants being greater than or equal to 1. The invention also relates to a cosmetic treatment process using said composition, especially a process for caring for and/or cleansing keratin materials.

Abstract: Disclosed is a composition comprising ascorbic acid or a derivative thereof, a silicone containing compound, and an essential oil, wherein at least 50% of the initial amount of the ascorbic acid in the composition remains stable when the composition is stored for at least 1 month at room temperature. The composition can be non-aqueous.

Abstract: Compositions of the invention contain, in a cosmetically acceptable aqueous medium, a) a cationic polyelectrolyte, b) at least one surfactant; and (c) from about 0.01 to about 1.2 weight percent of an anionic polyelectrolyte, where the weight ratio of the anionic polyelectrolyte to the cationic polyelectrolyte is from about 0.05 to about 1.2, and where the composition exhibits a viscosity change that is below a minimum significant-change-threshold (??min) and exhibits no measurable yield stress or increase in yield stress value when compared to a substantially identical composition that does not contain from about 0.01 to about 1.2 weight percent of the anionic polyelectrolyte, at a weight ratio of anionic polyelectrolyte to cationic polyelectrolyte of from about 0.05 to about 1.2.

Abstract: This application provides, among other things, novel aqueous biphasic oral care compositions comprising two distinct aqueous phases, useful for combining and delivering poorly compatible ingredients, for example to deliver effective levels of cationic antibacterial agents in combination with anionic polymers, e.g. that protect against erosion and staining, by addition of a stabilizing amount of a polyamine, e.g. lysine, and methods for making and using the same.

Abstract: A clear shampoo composition containing a silicone emulsion and a detersive surfactant. The silicone emulsion contains one or more silicone polymers that can be a polyorganosiloxane compound containing one or more quaternary ammonium groups, silicone blocks comprising between about 99 and about 199 siloxane units on average, at least one polyalkylene oxide structural unit; and at least one terminal ester group.

Abstract: An effervescent tablet that exhibits rapid disintegration is disclosed. The effervescent tablet includes an effervescent agent that includes an acid and a base, a directly compressible sugar binder, a sweetener that includes at least one of Stevia and Monk fruit, a flavor agent that includes a gum Arabic carrier, and a lubricant derived from rice hulls.

Abstract: A pharmaceutical long acting depot composition is provided as an aid to smoking cessation treatment. The formulation comprises a therapeutically effective amount of varenicline or its pharmaceutically acceptable derivative and pharmaceutically acceptable excipients. The process of preparation of the formulation is also provided.

Abstract: The present invention provides a composition suitable for forming an intramuscular implant. It comprises a biodegradable thermoplastic polymer of polylactic acid (PLA), DMSO and an aromatase inhibitor compound. The invention also provides a kit suitable for the in situ formation of the composition and its use as a medicine for treating cancer, especially breast cancer.

Abstract: Provided are a method of delivering target materials into extracellular vesicles including exposing the target materials and the extracellular vesicles to extracorporeal shockwaves, a method of preparing target material-introduced extracellular vesicles, extracellular vesicles prepared by the method, drug delivery vehicles including extracellular vesicles, and a method of delivering target materials into cells. The present disclosure exposes extracellular vesicles derived from natural organisms such as animal cells, plant cells, and microorganisms including bacteria and eukaryotic bacteria as well as artificially produced extracellular vesicles to extracorporeal shockwaves extracellularly. Thus, the high-level energy extracorporeal shockwaves can be used to deliver the target material into the extracellular vesicle efficiently. When treating with extracorporeal shockwaves, the ability of target material-introduced extracellular vesicles to incorporate into target cells also increases.

Abstract: Provided are a nanocomposite including a nano-drug delivery system; and a ginseng extract or a ginsenoside isolated therefrom, and a preparation method thereof, in which the nanocomposite may be used for the prevention or treatment of cancer and inflammatory diseases. The metal nanocomposite of the present invention may be prepared in a uniform size without using an additional reducing agent or stabilizing agent in a significantly shortened time, as compared with known metal nanoparticles. Further, since the metal nanocomposite has high solubility in water and high targeting ability for cancer cells, it can be advantageously developed as drugs. Further, the metal nanocomposite exhibits high anti-cancer and anti-inflammatory activities, and thus may be usefully applied to prevention or treatment of cancer and inflammatory diseases.

Abstract: A method of delivering a health care active having the steps of administering to a mammal in need of a health benefit or a treatment for a health condition a personal health care article and consuming the article. The article contains one or more filaments that contain a backbone material, a health care active and optionally aesthetic agents, extensional aids, plasticizers, and crosslinking agents.

Abstract: The present technology relates generally to devices for treatment of skin and skin conditions, as well as methods for preparing the devices and methods of treatment using the devices. Suitably, the devices comprise a hydrocolloid dressing and one or more active agents, wherein the amount of the active agent(s) does not reduce the absorption properties of the hydrocolloid dressing.

Abstract: A cannabinoid-based pharmaceutical composition for the prevention and treatment of pathogenic viruses (particularly those causing hepatic related conditions such as hepatitis B and C), and most particularly for hepatitis C virus (HCV) infection, having a cannabidiol structure or a pharmaceutically acceptable salt thereof. A method for the prevention and treatment of pathogenic viruses (particularly those causing viral hepatic related conditions such as hepatitis B and C), and most particularly for HCV is also disclosed.

Abstract: Methods of preventing the formation of liver cancer in a subject are described herein. In the disclosed methods, a prophylactically effective amount of safranal may be administered to a subject. In some embodiments, the subject may suffer from hepatic oxidative stress and/or hepatic inflammation. In another aspect, methods of preventing the formation of a liver cancer in a subject are disclosed that include monitoring the level of a liver cancer marker and administering a prophylactically effective amount of safranal to the subject, such that the effective amount is effective to maintain a normal level of the liver cancer marker.

Abstract: The invention relates to terpenes and uses thereof.

Abstract: Provided herein are compositions useful for treating inflammation in a subject and methods of decreasing inflammation in the skin, mucosa, and/or eye of a subject comprising applying a pharmaceutical composition that includes an NO-releasing compound to the skin, mucosa, and/or eye of the subject in an amount sufficient to decrease inflammation.

Abstract: The present invention provides drug therapy formulations for reducing the side effects associated with a therapeutic. In some embodiments, the present invention provides a reduction in sleep- and diet-related side effects associated with a therapeutic.

Abstract: Provided is a treatment of cancer using a dual modulator of Insulin Receptor Substrate (IRS) and signal transducer and activator of transcription 3 (Stat3), as well with other agents. The combination can be used to treat a tumor that has developed resistance to an EGFR inhibitor, EGFR antibody, mTOR inhibitor, MEK inhibitor, mutated B-Raf inhibitor, chemotherapeutic agents, and certain combinations thereof, or to prevent acquired resistance of a tumor to any of said inhibitors or agents, or to prevent tumor recurrence following cease of treatment with any of said inhibitors or agents or a combination thereof. The subject matter further provides a treatment of cancer using combination therapy comprising a dual modulator of IRS and Stat3, in combination with an immunotherapy agent. The combination can be used to sensitize a tumor to immunotherapy.

Abstract: This disclosure features chemical entities (e.g., a compound exhibiting activity as a mitochondrial uncoupling agent or a pharmaceutically acceptable salt and/or hydrate and/or cocrystal thereof, e.g., a compound, such as niclosamide or a pharmaceutically acceptable salt and/or hydrate and/or cocrystal thereof, e.g., a compound, such as a niclosamide analog, or a pharmaceutically acceptable salt and/or hydrate and/or cocrystal thereof) that are useful, e.g., for treating one or more symptoms of a pathology characterized by an abnormal inflammatory response (e.g., inflammatory bowel diseases) in a subject (e.g., a human). This disclosure also features compositions as well as other methods of using and making the same.

Abstract: The invention relates to a composition having antimicrobial and hygroscopic properties and the composition comprises a carboxylic acid compound as well as at least one C3-C6 diol and at least one C8-C12 diol. The composition of the invention may be used for cleansing, disinfection, surface treatment, impregnation and for antimicrobial treatment. The composition is particularly useful for treatment of fungal infections of the nail (onychomycosis).

Abstract: Disclosed herein are compositions including a compound of formula (I) for treating cancer. Some embodiments relate to methods of treating cancer by co-administering a compound of formula (I) and one or more immune checkpoint inhibitor to a subject in need thereof. Some embodiments relate to methods of treating cancer by co-administering a compound of formula (I) and plinabulin to a subject in need thereof. Some embodiments relate to methods of providing co-stimulation of T-cell activation against cancer by co-administering a compound of formula (I), one or more immune checkpoint inhibitor.

Abstract: The present invention relates to a conjugate salt of N,N-dimethylglycine with metal and organic acid, and a preparation method and use thereof. The conjugate salt of N,N-dimethylglycine with metal and organic acid has a following structural formula: [(CH3)2NCH2COO]nM.[Organic acid], wherein, n is 1 or 2; M is selected from an alkali metal ion or a divalent metal ion; the organic acid is selected from an organic polyacid, a C2-C18 linear fatty acid or an aromatic acid. The conjugate salt of N,N-dimethylglycine with metal and organic acid is a conjugate acid salt formed by introducing another organic acid with a hydrophobic group into the salt of N,N-dimethylglycine and a metal ion, so as to modify the hygroscopicity of N,N-dimethylglycine by decreasing the affinity of the salt toward water molecules in the air, or decreasing the affinity or attraction of molecular aggregates formed through crystalline behavior of the salt toward water molecules in the air.

Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.

Abstract: Disclosed herein are compositions comprising fixed doses of ETC-1002 and Ezetimibe. Also disclosed herein are methods for using fixed doses of ETC-1002 and Ezetimibe. Uses include methods of treating cardiovascular disease or reducing the risk of cardiovascular disease in a subject. Uses also include methods of treating hypercholesterolemia in a subject.

Abstract: The invention relates to compositions and devices which include an osmolytic agent, in particular a betaine or carnitine compound, for reducing ocular discomfort associated with various diseases or conditions, in particular diseases or conditions associated with high tear film tonicity. The invention also relates to methods of treating or preventing various diseases or conditions using compositions and devices of the invention.

Abstract: A topical skin care composition for rejuvenation of the skin containing tetracaine, purified water, stearic acid, lauramide diethanolamine, beeswax, propylene glycol, sodium tetraborate, sodium lauryl sulfate, benzyl alcohol, glycerin, diazolidinyl urea, triethanolamine, methyl salicylate, and eucalyptus oil. The topical skin care composition of the invention is useful in the healing of the skin and in particular, after the skin has been exfoliated.

Abstract: The present invention relates to carbamoyl phenylalaninol compounds and methods of using the same to treat disorders. The invention further relates to the development of methods for treating excessive sleepiness in a subject, e.g., due to narcolepsy or obstructive sleep apnea, with the surprising outcome that “normal” levels of wakefulness are achieved based on standard objective and subjective sleepiness tests.

Abstract: Disclosed are small molecule therapeutic compounds that are potent inhibitors of arginase 1 and arginase 2 activity. Also disclosed are pharmaceutical compositions comprising the compounds, and methods for using the compounds for treating or preventing a disease or condition associated with arginase activity.

Abstract: Pharmaceutical composition comprising an aqueous solution of a taxane and an aqueous solution of a hydrophobic statin intended for use in treatment or prevention of human melanoma.

Abstract: The invention relates to a composition comprising isoflavones from red clover. The red clover extract has been fermented to obtain a composition comprising aglycone isoflavones. The fermentation is preferably performed by a lactic acid bacteria or fermented dandelion extract.

Abstract: A formulation comprising at least one ketogenic agent, at least one cannabinoid, at least one polyphenol, at least one phytonutrient, at least one dietary nutrient, at least one antioxidant, and at least one mineral, and mixtures and combinations thereof utilized for performance, cardiometabolic, cognitive, and women's health and wellness.

Abstract: Methods of treating a methicillin-resistant Staphylococcus aureus (MRSA) infection or a Staphylococcus pseudintermedius infection in subject in need thereof are provided, the methods comprising administering to the subject an effective amount of a topical gel composition comprising vitamin E d-alpha-tocopherol polyethylene glycol 1000 succinate (TPGS); and at least one lipophile. Compositions, methods of manufacture, and methods of use in inhibiting microbial growth are also provided.

Abstract: The present invention relates to a method for inhibiting a cancer metastasis in a subject in need thereof, comprising administering to said subject a cancer metastasis-inhibiting effective amount of: Camphorataimide B; or a composition comprising Camphorataimide B and a pharmaceutically acceptable adjuvant, vehicle, or carrier.

Abstract: The present invention concerns methods and compositions involving inhibitors and of RAD51, a protein involved in homologous recombination. In some embodiments, there are methods for sensitizing cells to the effects of DNA damaging agents, which can have particular applications for cancer patients. In some embodiments of the invention, the RAD51 inhibitor is a small molecule that directly affects RAD51 activity, such as its ability to promote filament formation.

Abstract: The present invention relates to non-hormonal compositions and methods for inducing a condition of aspermia, azoospermia, or severe oligozoospermia in the male subject such that these compositions and methods for administering the same may be used as male contraception. Embodiments of the present invention may comprise a composition comprising an alpha-1-adrenoreceptor antagonist, such as (R)-silodosin, for daily administration to a male subject. The compositions and related methods may further include pharmaceutically acceptable carriers. The present invention further includes formulations which allow for a delay such that delayed or missed dose(s) do not nullify the contraceptive effect of the treatment regimen. Such compositions and methods may also avoid the side effects associated with typical formulations of alpha-1-adrenoreceptor antagonists.